JSS Sustainable Equity - Future Health E CHF acc

Reference Data

ISIN LU2041628244
Valor Number 49478504
Bloomberg Global ID
Fund Name JSS Sustainable Equity - Future Health E CHF acc
Fund Provider J. Safra Sarasin Investmentfonds AG Basel, Switzerland
Phone: +41 58 317 44 44
Web: www.jsafrasarasin.com
Fund Provider J. Safra Sarasin Investmentfonds AG
Representative in Switzerland J. Safra Sarasin Investmentfonds AG
Basel
Phone: +41 58 317 44 00
Distributor(s) Bank J. Safra Sarasin AG
Basel
Phone: +41 58 317 44 00
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD).
Peculiarities

Fund Prices

Current Price * 97.00 CHF 21.11.2024
Previous Price * 96.66 CHF 20.11.2024
52 Week High * 107.80 CHF 16.07.2024
52 Week Low * 88.02 CHF 28.11.2023
NAV * 97.00 CHF 21.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 130,220,626
Unit/Share Assets *** 14,973,432
Trading Information SIX

Performance

YTD Performance +6.95% 29.12.2023
21.11.2024
1 month -5.22% 21.10.2024
21.11.2024
3 months -6.78% 21.08.2024
21.11.2024
6 months -7.11% 21.05.2024
21.11.2024
1 year +9.63% 21.11.2023
21.11.2024
2 years -11.24% 21.11.2022
21.11.2024
3 years -24.38% 22.11.2021
21.11.2024
5 years -3.00% 21.11.2019
21.11.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 8.43%
Danaher Corp 5.66%
Boston Scientific Corp 5.07%
Sanofi SA 4.97%
Novo Nordisk AS Class B 4.31%
Pfizer Inc 3.77%
Zoetis Inc Class A 3.67%
Biomarin Pharmaceutical Inc 3.54%
Gilead Sciences Inc 3.51%
Merck & Co Inc 3.50%
Last data update 30.09.2024

Cost / Risk

TER 1.57%
TER date 30.04.2024
Performance Fee ***
PTR
Max. Management Fee *** 1.80%
Ongoing Charges *** 1.52%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 *** GMOs

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)